ASH 2022 | RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphoma

Michael LaRiviere, MD, University of Pennsylvania, Philadelphia, PA, shares some insights into a novel ‘radiation vaccine’ treatment approach being explored in the RadVax trial (NCT03495713), which involves using radiation therapy to stimulate neoantigen release and induce anti-tumor adaptive immune responses in patients with aggressive Hodgkin lymphoma (HL). In this study, patients received the PD1 inhibitor nivolumab, and subsequently received low-dose radiation if they failed to show a complete response (CR). This study demonstrated that disease did not progress at the sites that were treated with radiation. Dr LaRiviere suggests that future studies will be needed to clarify whether more extensive diseases can be treated with radiation, describing an ongoing trial that is investigating the use of radiation vaccines in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.